The combination is now used as part of the complete treatment regimen for locally advanced or early-stage HER2-positive cancer and as adjuvant treatment for early-stage HER2-positive breast cancer with high risk of reoccurrence. The gene discussed is ERBB2; the disease is breast cancer.